

Company name---ZygoFix- * Website--- www.zygofix.com -- *

CEO name---Ofer Levy ---- *

Select a CATEGORY: Medical Devices

Select one SESSION per abstract from the list below *

“Beyond Bones and Screws: Rethinking Orthopedic Repair”

- Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.
 - ZygoFix is redefining treatment for chronic back pain with its anatomy-conforming implant, designed for insertion into the facet joint as a lasting solution for facet arthritis. It targets patients who have exhausted conservative therapies, representing over one million patients in the US and a \$5B market, supported by eight years of clinical success, CE and FDA clearance, and initial US commercialization.
- Core Technology: What is the technology, its uniqueness, and its value proposition?
 - ZygoFix has developed a miniature 3D printed bendable implant that conforms to the spine's anatomy during insertion and provides unparalleled direct stabilization for the treatment of lumbar spine degenerative pathologies. The company's zLOCK system leverages the spine's natural anatomy for a lasting minimally invasive treatment, enabling to take the procedure out of the hospital as an advanced outpatient solution.
- Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.
 - zLOCK is currently used by Spine Surgeons in the US for lumbar fusions in a variety of indications and procedures from single segment to multi-level high risk surgeries. Future developments include widening customer base to interventional pain physicians enabled due to its unique conforming design that allows stand-alone placement. The patented conforming technology is also suitable for SI and cervical fusions.
- Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.
 - The company has setup office in the US and works with a base of early adopters to showcase the technology and create traction. At a 2nd stage, the company intends to widen its outreach to a wider surgeon market while accommodating the system for pain management where it provides a differentiated solution to an unmet need.
- What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans
 - The company is raising its round A of \$10M to support its continues growth:
 - Grow its executive US team
 - Advance a percutaneous disposable version of the system to suite the pain management market
 - Conduct post market studies to report on its efficacy and support market expansion

